Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Debt to Equity (2020)

Foghorn Therapeutics has reported Debt to Equity over the past 1 years, most recently at $0.13 for Q4 2020.

  • Quarterly results put Debt to Equity at $0.13 for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was $0.13 (changed N/A YoY), and the annual figure for FY2020 was $0.13, changed.
  • Debt to Equity for Q4 2020 was $0.13 at Foghorn Therapeutics, up from -$0.11 in the prior quarter.
  • Over the last five years, Debt to Equity for FHTX hit a ceiling of $0.13 in Q4 2020 and a floor of -$0.11 in Q3 2020.